Global Veterinary Anti-infectives market Segmented by Veterinary disease types, by animal types & By Geography - Trends & Forecasts (2017 - 2022)

The global market for veterinary anti-infectives is estimated to be worth USD 4,298 million in 2014. Expected to grow at a healthy CAGR of 6.35%, the market is set to reach USD 6,218 million by 2020. Global veterinary healthcare offers services and products in various segments such as vaccines, parasiticides, anti-infectives, medicinal feed additives, other pharmaceuticals, out of which anti-infectives are growing at a steady pace to combat the increasing number of infectious diseases in animals. It is the second best segment after vaccines and holds about 20% of the global animal healthcare market share.

Global Veterinary Anti-Infectives Market- Market Dynamics

The report studies various driving and restraining factors for the global veterinary anti-infectives market. Some of these are listed below.


Increase in pet ownership

Improved nutrition

Increasing zoonotic and foodborne diseases


Increased competition for cultivated land and cost-effective production are the major obstacles in the path of global veterinary anti-infectives market.

The report highlights the segment-wise contribution of different anti-incentives by disease, species, and geography. By type of products, the market has been segmented into marbofloxacin, florfenicol, freeze-dried ceftiofur, beta-lactams, oxytetracycline, and aminosidine; by species into companion and farm animals and by geography into North America, Asia-Pacific, Europe and Rest of World.

Some of the key players in the market are:

Bayer Healthcare

Boehringer Ingelheim

Ceva Animal Health, Inc.



Merial (Animal Health Division of Sanofi)

What the Report Offers

Market definition for the specified topic along with identification of key drivers and restraints for the market.

Market analysis for the veterinary anti-infectives market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the veterinary anti-infectives market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

1.1 Market Definition

1.2 Market Recent Trends

2.Market Analysis

2.1 Market Animal Health Products

2.2 Animal medicines vs. human Medicines

3.Market Dynamics

3.1 Market Drivers

3.1.1 Increase in pet ownership

3.1.2 Improved Nutrition

3.1.3 Intensifying consumer focus on food safety

3.1.4 Greater Livestock production

3.1.5 Increasing Zoonotic and Foodborne Diseases

3.2 Market Constraints

3.2.1 Scarcity of arable land and water

3.2.2 Increased competition for cultivated land

3.2.3 Cost effective production

3.3 Porter's Five Force Analysis

3.3.1 Threat of New Entrant

3.3.2 Internal Rivalry

3.3.3 Buyer bargaining power

3.3.4 Supplier bargaining power

3.3.5 Threat of substitutes

4.Global Veterinary Anti-Infective Market Segmentation

4.1 Global Veterinary Anti-infectives Market, By disease

4.1.1 Marbofloxacin

4.1.2 Florfenicol

4.1.3 Freeze-dried ceftiofur

4.1.4 Beta-lactams

4.1.5 Oxytetracycline

4.1.6 Aminosidine

4.2 Global Veterinary Anti-Infectives Market, By species

4.2.1 Companion Animals Cats Horses

4.2.2 Farm animal Cattle Swine Poultry Fish Sheep

4.3 Global Veterinary Anti-Infectives Market Segmentation, By Geography

4.3.1 North America US Mexico Canada

4.3.2 Europe France Italy Germany Spain Sweden Rest of Europe

4.3.3 Asia-Pacific India China Japan Rest of Asia-Pacific

4.3.4 Rest of the World

5. Competitive landscape

5.1 Major players in the market

5.2 mergers and acquisitions

5.3 New product launches

5.4 Agreement, Collaborations, and Partnerships

5.5 Recommendations for New players in the market

5.6 Recommendations for Existing players in the market

6. Company profiles

6.1 Zoetis animal healthcare

6.1.1 Financial Overview

6.1.2 Business overview

6.1.3 Business strategies

6.2 Merck

6.2.1 Financial Overview

6.2.2 Business overview

6.2.3 Business strategies

6.3 Merial (Animal Health Division Of Sanofi)

6.3.1 Financial Overview

6.3.2 Business overview

6.3.3 Business strategies

6.4 Elanco

6.4.1 Financial Overview

6.4.2 Business overview

6.4.3 Business strategies

6.5 Bayer healthcare

6.5.1 Financial Overview

6.5.2 Business overview

6.5 3 Business strategies

6.6 Ceva Animal Health, Inc.

6.6.1 Financial Overview

6.6.2 Business overview

6.6.3 Business strategies

6.7 Virbac

6.7.1 Financial Overview

6.7.2 Business overview

6.7.3 Business strategies

6.8 Boehringer Ingelheim

6.8.1 Financial Overview

6.8.2 Business overview

6.8.3 Business strategies

7. Appendix

7.1. Abbreviations

7.2. Sources

7.3. Bibliography

7.4. Disclaimer

Content are not available

Choose License Type